NIH clears first human safety study of isolated mitragynine for opioid use disorder

Why it matters

An FDA-cleared IND allows researchers to test purified mitragynine in people, providing the first controlled human safety data for this kratom alkaloid as a possible OUD treatment.

The big picture

NIH and University of Florida researchers developed the purified formulation and supporting preclinical package. The planned phase I study will establish safety and tolerability before efficacy questions can be answered.

Key findings

• The IND is now in effect with FDA; the trial is NIH-led and phase I; investigators plan a randomized double-blind placebo-controlled design; preclinical studies found no significant safety concerns across several animal doses.

What they say

NIDA Director Nora Volkow called the IND a major step toward expanding treatment options for people with opioid use disorder.

Bottom line

**The milestone is permission to begin human safety testing, not evidence that mitragynine treats OUD.**